CDKN2A and cancer: For example, a study of 100 benign and 105 malignant thyroid tumors using a panel of 57 molecular markers found an association of tumor pathology with the expression of a subset of markers including cytokeratin 19 (CK19), LGALS3, HBME-1, VEGF, AR, p16, and AURKA [49].